

**LISTING OF CLAIMS:**

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Please amend the claims as follows:

1-21. (Canceled).

22. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of unitary doses of viral particles of recombinant adenoviral vectors,

wherein said unitary dose comprises from about 10<sup>7</sup> to about 10<sup>14</sup> viral particles;

wherein the adenoviral vectors comprise an adenoviral genome replaced with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter, a tissue-specific promoter, or a combination thereof, that encodes for one or more therapeutic proteins for the treatment of fibrotic disorders in organs;

and a pharmaceutically compatible carrier,

wherein the therapeutic proteins for the treatment of fibrotic disorders is selected from the group consisting of one or more of the following or combinations thereof:

(i) a latent or active protein selected from the group consisting of matrix metalloprotease-8 (“MMP-8”), matrix metalloprotease-1, matrix metalloprotease-2, matrix metalloprotease-9, matrix metalloprotease-13 and combinations thereof;

(ii) wild type or modified urokinase plasminogen activator (“uPA”) or combinations thereof;

(iii) the truncated receptor for transforming growth factor-β (“TGF-β”) type II;

(iv) hepatocyte growth factor (“HGF”);

(v) betaglycan; and

(vi) Smad-7

~~wherein the therapeutic proteins for the treatment of fibrotic disorders the latent and/or active protein MMP-8, MMP-1, MMP-2, MMP-9 and MMP-13, uPA wild type and/or modified; the truncated receptor for TGF- $\beta$  type II; betaglycan; HGF and Smad-7.~~

23. (Canceled).

24. (Previously Presented) A method of treating fibrotic disorders in a patient, comprising:

preparing a recombinant adenoviral vector containing a therapeutic gene or DNA sequence;  
delivering the recombinant adenoviral vector by an administrative route to an organ; and  
generating therapeutic proteins in the organ from the recombinant adenoviral vector to treat the fibrotic disorders.

25. (Previously Presented) The method of claim 24, wherein the administrative route is intravenous.

26. (Previously Presented) The method of claim 24, wherein the organ is selected from liver, lung, heart, kidney, skin, hypertrophic scars, and combinations thereof.

27. (Previously Presented) The method of claim 24, wherein the fibrotic disorders are hepatic fibrosis, pulmonary fibrosis, renal fibrosis, heart fibrosis, keloids, hypertrophic scars, or combinations thereof.

28. (Currently Amended) The pharmaceutical composition according to claim 22, wherein the administration route is intravenous wherein the therapeutic protein for the treatment of fibrotic disorders comprises MMP-8.

29. (Currently Amended) The pharmaceutical composition according to claim 22, wherein the organs with fibrosis are liver, lung, heart, kidney, skin, and hypertrophic scars wherein the therapeutic protein for the treatment of fibrotic disorders comprises MMP-1.

30. (Currently Amended) The pharmaceutical composition according to claim 29, wherein the liver is cirrhotic liver wherein the therapeutic protein for the treatment of fibrotic disorders comprises the truncated receptor for TGF- $\beta$  type II.

31. (Currently Amended) The pharmaceutical composition according to claim 22, wherein the composition is useful in the treatment of the hepatic fibrosis, pulmonary fibrosis, renal fibrosis, heart fibrosis, keloids and hypertrophic scars wherein the therapeutic protein for the treatment of fibrotic disorders comprises wild type or modified uPA or combinations thereof.

32. (Currently Amended) The pharmaceutical composition according to claim 22, which does not induce lethal toxicity wherein the therapeutic protein for the treatment of fibrotic disorders comprises HGF.